Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Conjugation of VEGFR1/R2-targeting peptide with gold nanoparticles to enhance antiangiogenic and antitumoral activity

Fig. 3

GNP-VGB3 recognizes VEGFR1 and VEGFR2 and suppresses their VEGF-induced phosphorylation in endothelial cells. a Immunocytochemical images of HUVE cells treated with PBS, GNP, VGB3 and GNP–VGB3 using FITC-secondary anti-mouse antibody (green) to bind to VEGFR1 (left) and VEGFR2 (right) (scale bar: 20 μm). b Statistical analysis of VEGFR1/2 fluorescence intensity under various concentrations were performed by prism software 8; Oneway ANOVA and all data displayed mean ± SEM (n = 3). c Immunoflourescent staining images (PE-secondary anti-mouse antibody (red)) of phosphorylated-VGEFR1 (p-VEGFR1) and p-VEGFR2 with various treatments. d Quantitative analysis of the fluorescence intensity of p-VEGFR1/2 by prism software 8 analyzed by One-way ANOVA for different treatments. (****P < 0.0001, ***P < 0.001 and NS: not significant in comparison with control)

Back to article page